Both Cytyc and Digene are regarded as models of marketing success and growth in Diagnostics, best practice companies. Both had strong patient advocacy available. Cellestis’ market growth is easily comparable.
Easily comparable. Thanks Tony, I like easy.
So what does all this mean ?
''It's very foolish of anyone to make up their mind ... before they've allowed a very rational debate on the future and potential [of Cellestis],''and this
Cellestis has not been involved in any of the financial analysis, including any assumptions contained within that financial analysis, contained within information disseminated by any shareholder that may be representing the Cellestis Shareholder Action Group.and this
The Cellestis Board unanimously recommends that the Cellestis Shareholders vote in favour of the Scheme, and intend to vote the shares that they control, in favour of the Scheme..There is no Scheme Booklet, no Independent Expert report and as far as I can see, no rational debate - just a whole heap of foolish assumptions made by Cellestis regarding shareholders.
